Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 5/2018

01-05-2018 | Original Article

Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

Authors: Alessandro Vitale, Quirino Lai, Fabio Farinati, Laura Bucci, Edoardo G. Giannini, Lucia Napoli, Francesca Ciccarese, Gian Lodovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Rodolfo Sacco, Giuseppe Cabibbo, Roberto Virdone, Fabio Marra, Martina Felder, Filomena Morisco, Luisa Benvegnù, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Antonio Colecchia, Mauro Bernardi, Franco Trevisani, Timothy M. Pawlik, On behalf of the Italian Liver Cancer (ITA.LI.CA) group

Published in: Journal of Gastrointestinal Surgery | Issue 5/2018

Login to get access

Abstract

Background

Dichotomous models like Milan Criteria represent the routinely used tools for predicting the outcome of patients with hepatocellular carcinoma (HCC). However, a paradigm shift from a dichotomous to continuous prognostic stratification should represent a good strategy for improving the prediction process. Recently, the tumor burden score (TBS) has been proposed for selecting patients with colorectal liver metastases. To date, TBS has not been validated in a large HCC population. The main objective of this study was to evaluate the prognostic power of TBS in an HCC population treated with different curative and palliative modalities.

Methods

Prospectively collected data from consecutive HCC patients managed in 24 institutions participating in the ITA.LI.CA group between Jan 2002 and Mar 2015 were analyzed (n = 4759). A sub-analysis focused on 3909 patients with the radiological evidence of vascular invasion or metastatic disease was also performed.

Results

TBS demonstrated the best discriminative ability when compared to MC and other tumor-specific scores. At multivariable Cox regression analysis, TBS was an independent risk factor of overall survival, with a 6% increased risk for patient death for each point increase in TBS. At survival analysis, when TBS ≥ 8 was connected with MELD ≥ 15 and alpha-fetoprotein ≥ 1000 ng/mL, patients presenting all these three risk factors presented the worst results (p value < 0.0001).

Conclusions

Survival prediction of HCC patients was very well done using TBS model, even stratifying the population in relation to the presence of metastases and/or vascular invasion. TBS model was the best in terms of discriminatory ability and goodness of fit when compared with other continuous or binary variables. Its incorporation in a model composed by tumor- and liver function-related variables further increases its survival prediction.
Literature
1.
go back to reference Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9.CrossRefPubMed Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9.CrossRefPubMed
2.
go back to reference Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L: Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17:S44–57.CrossRefPubMed Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L: Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17:S44–57.CrossRefPubMed
3.
go back to reference Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J; EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–30.CrossRefPubMed Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J; EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–30.CrossRefPubMed
4.
go back to reference EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma: J Hepatol 2012;56:908–943.CrossRef EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma: J Hepatol 2012;56:908–943.CrossRef
5.
go back to reference Bruix J, Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.CrossRefPubMedPubMedCentral Bruix J, Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.CrossRefPubMedPubMedCentral
6.
go back to reference Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U; Italian Liver Cancer (ITA.LI.CA) group: Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol 2015;62:617–24.CrossRefPubMed Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U; Italian Liver Cancer (ITA.LI.CA) group: Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol 2015;62:617–24.CrossRefPubMed
7.
go back to reference Toso C, Kneteman NM, James Shapiro AM, Bigam DL: The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009;22:869–75.CrossRefPubMed Toso C, Kneteman NM, James Shapiro AM, Bigam DL: The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009;22:869–75.CrossRefPubMed
8.
go back to reference Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35–43.CrossRefPubMed Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35–43.CrossRefPubMed
9.
go back to reference Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, Kumamoto T, Iacono C, Andreatos N, Guglielmi A, Endo I, Pawlik TM: The Tumor Burden Score: A New "Metro-ticket" Prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 2018;267:132–141.CrossRefPubMed Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, Kumamoto T, Iacono C, Andreatos N, Guglielmi A, Endo I, Pawlik TM: The Tumor Burden Score: A New "Metro-ticket" Prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 2018;267:132–141.CrossRefPubMed
10.
go back to reference Akaike’s criteria. In: Armitage P, Colton T, eds Encyclopedia of Biostatistics. Chichester: Wiley; 1998. p. 123–124. Akaike’s criteria. In: Armitage P, Colton T, eds Encyclopedia of Biostatistics. Chichester: Wiley; 1998. p. 123–124.
11.
go back to reference Rodriguez JD, Perez A, Lozano JA. Sensitivity analysis of k-fold cross validation in prediction error estimation. IEEE Trans Pattern Anal Mach Intell 2010;32:569–575.CrossRefPubMed Rodriguez JD, Perez A, Lozano JA. Sensitivity analysis of k-fold cross validation in prediction error estimation. IEEE Trans Pattern Anal Mach Intell 2010;32:569–575.CrossRefPubMed
12.
go back to reference Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, Levy GA, Greig PD, Grant DR: Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006;81:1633–9.CrossRefPubMed Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, Levy GA, Greig PD, Grant DR: Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006;81:1633–9.CrossRefPubMed
13.
go back to reference Lee DH, Lee JM, Baek JH, Shin CI, Han JK, Choi BI: Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Radiology 2015;274:149–60.CrossRefPubMed Lee DH, Lee JM, Baek JH, Shin CI, Han JK, Choi BI: Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Radiology 2015;274:149–60.CrossRefPubMed
14.
go back to reference Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in 18 multiple regression: a bad idea. Stat Med. 2006 Jan 15;25(1):127–41.CrossRefPubMed Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in 18 multiple regression: a bad idea. Stat Med. 2006 Jan 15;25(1):127–41.CrossRefPubMed
15.
go back to reference Mazzaferro V: Results of liver transplantation: with or without Milan criteria? Liver Transpl 2007;13:S44–7.CrossRefPubMed Mazzaferro V: Results of liver transplantation: with or without Milan criteria? Liver Transpl 2007;13:S44–7.CrossRefPubMed
16.
go back to reference Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–403.CrossRefPubMed Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–403.CrossRefPubMed
17.
go back to reference Lai Q, Avolio AW, Manzia TM, Sorge R, Agnes S, Tisone G, Berloco PB, Rossi M: Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant 2012;26:E125–31.CrossRefPubMed Lai Q, Avolio AW, Manzia TM, Sorge R, Agnes S, Tisone G, Berloco PB, Rossi M: Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant 2012;26:E125–31.CrossRefPubMed
18.
go back to reference Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AM, Kneteman NM: Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008;14:1107–15.CrossRefPubMed Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AM, Kneteman NM: Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008;14:1107–15.CrossRefPubMed
19.
go back to reference Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM: Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 2015;62:158–65.CrossRefPubMed Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM: Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 2015;62:158–65.CrossRefPubMed
20.
go back to reference Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-Uso T, Quintini C, Eghtesad B, Fung JJ, Aucejo FN, Miller CM: Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. Lancet Gastroenterol Hepatol 2017;2:595–603.CrossRefPubMed Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-Uso T, Quintini C, Eghtesad B, Fung JJ, Aucejo FN, Miller CM: Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. Lancet Gastroenterol Hepatol 2017;2:595–603.CrossRefPubMed
21.
go back to reference Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group: Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med 2016;13:e1002006.CrossRefPubMedPubMedCentral Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group: Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med 2016;13:e1002006.CrossRefPubMedPubMedCentral
22.
go back to reference Lerut J, Lai Q: Morphology does not tell us the entire story: biological behavior improves our ability to select patients with hepatocellular carcinoma waiting for liver transplantation. Hepatobiliary Pancreat Dis Int 2015;14:570–1.CrossRefPubMed Lerut J, Lai Q: Morphology does not tell us the entire story: biological behavior improves our ability to select patients with hepatocellular carcinoma waiting for liver transplantation. Hepatobiliary Pancreat Dis Int 2015;14:570–1.CrossRefPubMed
23.
go back to reference Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Fagiuoli S, Farinati F, Rugge M, D'Amico DF: Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150–9.CrossRefPubMedPubMedCentral Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Fagiuoli S, Farinati F, Rugge M, D'Amico DF: Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150–9.CrossRefPubMedPubMedCentral
24.
go back to reference Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY: Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013;19:1343–53.CrossRefPubMed Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY: Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013;19:1343–53.CrossRefPubMed
25.
go back to reference Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D; Liver Transplantation French Study Group: Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986–94.CrossRefPubMed Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D; Liver Transplantation French Study Group: Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986–94.CrossRefPubMed
26.
go back to reference Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group: Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013;19:1108–18.CrossRefPubMed Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group: Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013;19:1108–18.CrossRefPubMed
27.
go back to reference Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J: Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 2014;27:32–41.CrossRefPubMed Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J: Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 2014;27:32–41.CrossRefPubMed
Metadata
Title
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group
Authors
Alessandro Vitale
Quirino Lai
Fabio Farinati
Laura Bucci
Edoardo G. Giannini
Lucia Napoli
Francesca Ciccarese
Gian Lodovico Rapaccini
Maria Di Marco
Eugenio Caturelli
Marco Zoli
Franco Borzio
Rodolfo Sacco
Giuseppe Cabibbo
Roberto Virdone
Fabio Marra
Martina Felder
Filomena Morisco
Luisa Benvegnù
Antonio Gasbarrini
Gianluca Svegliati-Baroni
Francesco Giuseppe Foschi
Gabriele Missale
Alberto Masotto
Gerardo Nardone
Antonio Colecchia
Mauro Bernardi
Franco Trevisani
Timothy M. Pawlik
On behalf of the Italian Liver Cancer (ITA.LI.CA) group
Publication date
01-05-2018
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 5/2018
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-018-3688-y

Other articles of this Issue 5/2018

Journal of Gastrointestinal Surgery 5/2018 Go to the issue